Latest Repertoire Immune Medicines News & Updates
See the latest news and media coverage for Repertoire Immune Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing immune medicines
repertoire.com- Headquarters
- Cambridge, United States
- Founded year
- 2020
- Company type
- Private company
- Number of employees
- 80–200
Latest news about Repertoire Immune Medicines
Company announcements
-
Repertoire Immune Medicines shares exciting R&D achievement
The accomplishment highlights the agility and perseverance of their talented R&D group advancing cancer therapy urgently.
-
Repertoire Immune Medicines doses first participant in RPTR-1-201 trial
The Phase 1/2 trial evaluates safety, tolerability, and antitumor activity of the TCR bispecific therapy for advanced solid tumors, as monotherapy and with anti-PD-1.
-
Repertoire announces strategic collaboration with Lilly
The partnership uses Repertoire's DECODE platform to develop tolerizing therapies for autoimmune diseases. Lilly leads clinical development and commercialization.
-
Flagship Pioneering and Repertoire announce agreement for T-cell therapies
Repertoire and Pioneering Medicines will use DECODE platform to identify TCR bispecifics for metastatic prostate cancer under Pfizer partnership. This is the eighth program.
Media coverage
-
Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has been...
-
Repertoire Immune Medicines Enters $1.9 Billion Collaboration with Eli Lilly to Develop Autoimmune Disease Therapies | PharmExec
The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving immune responses at their source.
-
Repertoire and Lilly join hands on autoimmune disease therapies
Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several autoimmune diseases.
-
Flagship's Repertoire gets another autoimmune partner as Lilly invests initial $85M
Repertoire Immune Medicines partners with Eli Lilly in $85M upfront deal, potential $1.84B in milestone payments for autoimmune disease tolerizing vaccines collaboration.
Track Repertoire Immune Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Repertoire Immune Medicines competitors & trending companies
Browse news for competitors to Repertoire Immune Medicines and other trending companies.
Abcuro
Alligator Bioscience
BioInvent
Nektar
Candel Therapeutics
Orna Therapeutics
Immutep
Imugene
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group